Tranzyme Pharma Announces First Quarter 2013 Financial Results
09 mai 2013 16h30 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., May 9, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel,...
Tranzyme Pharma to Report First Quarter 2013 Financial Results
02 mai 2013 05h10 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., May 2, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the Company will report first quarter 2013 financial results after the close of the...
Tranzyme Pharma and Ocera Therapeutics Announce Merger Agreement
23 avr. 2013 19h37 HE
|
Ocera Therapeutics, Inc.
$20M Committed PIPE Financing to Close With Merger
– Joint Conference Call Scheduled for April 24, 2013 at 8:00am ET –
RESEARCH TRIANGLE PARK, N.C. and SAN DIEGO, April 23, 2013...
Tranzyme Pharma Announces Fourth Quarter and Full-Year 2012 Financial Results
28 mars 2013 16h30 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., March 28, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel,...
Tranzyme Pharma to Report Fourth Quarter and Full-Year 2012 Financial Results
13 mars 2013 17h55 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., March 13, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the Company will report fourth quarter and full-year 2012 financial results after...
Tranzyme Pharma Announces Exploration of Strategic Alternatives
08 févr. 2013 05h10 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Tranzyme, Inc. (Nasdaq:TZYM) announced today that its Board of Directors has made a determination to explore and evaluate strategic...
Tranzyme Pharma Promotes David Moore to Chief Business Officer
15 janv. 2013 05h10 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 15, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that David S. Moore has been named as Chief Business Officer.
"Dave has provided...
Tranzyme Pharma Announces Successful Completion of Drug Discovery Collaboration With Bristol-Myers Squibb
04 janv. 2013 05h10 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule...
Tranzyme Pharma's DIGEST Trial Stopped for Futility After Interim Analysis of the Phase 2b Results
17 déc. 2012 08h00 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b...
Tranzyme Pharma Announces Resignation of Chief Financial Officer
05 déc. 2012 16h15 HE
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Richard I. Eisenstadt, Vice President, Finance and Chief Financial Officer, has...